Medical Devices Group Procurement Enters Its Second Half — Order Structures Are Concentrating Toward “Fewer SKUs, Larger Batches”

Medical Devices: Group Procurement Enters Its Second Half — Order Structures Are Concentrating Toward “Fewer SKUs, Larger Batches”

In the autumn of 2026, a set of figures from the orthopedic implant precision machining sector has been circulating repeatedly in supply chain circles: group-procurement-winning leaders hold over 80% of regional market share, with orders concentrated on a handful of best-selling models. Previously, a precision machining supplier might have produced parts to different specifications for 5–10 brands, with annual demand of 500–2,000 units per SKU. After group procurement, orders concentrate on 2–3 core SKUs, and annual demand per SKU jumps to 5,000–20,000 units.

This shift is not unique to orthopedics. In the seventh national high-value consumables procurement round, a single category — endoscopic hemostatic clips — had first-year demand of 10.888 million units, accounting for 56.5% of all 23 categories. Hemostatic clips, hot biopsy snares, and injection needles together made up 90.1% of total demand. Reported volumes themselves are concentrating on a few categories, and the order structure on the supplier side is shifting accordingly.

I. What “Second Half” Actually Means: Price Anchors Are No Longer Drifting Violently

To understand why order concentration is accelerating now, it helps to see what changed in the procurement rules themselves.

The seventh round abandoned the single anchor of “average winning bid × 65%” and introduced a dual-anchor and standard-deviation mechanism: bids below one standard deviation from the average are excluded from the price-gap calculation baseline; bids below two standard deviations are accepted as winning but receive zero agreed procurement volume — six products triggered this rule. The design intent is clear: exclude extreme low bids from anchor calculation and keep winning prices in a “reasonable range” rather than continuing a downward race.

This changes how group procurement transmits pressure to the upstream supply chain. In earlier rounds, the core pressure was rapid end-price decline, with OEMs pushing price cuts up the chain and machining quotations being compressed round after round. As price anchors stabilize, OEMs’ competitive focus shifts from “who is cheaper” to who can deliver a committed volume at a stable cost. Orthopedic data supports this: average prices fell 50–80%, but volumes grew 30–40%, and the market did not shrink — profit distribution simply shifted from “many varieties, small batches, high margin” to “few varieties, large batches, efficiency-driven”.

II. The Real Pressure of Scale: Not “Can You Make It,” but “Is Unit 10,000 the Same as Unit 1”

Scaling from 500–2,000 units per year to 5,000–20,000 units sounds like a quantity change. But for precision machining, scaling amplifies process variation that small batches had masked.

Take laparoscopic stapler cartridge slots and ultrasonic scalpel tips. The single-piece machining difficulty is not extreme; the real challenge is mold life management and process window stability. An MIM mold can produce fully qualified samples during trial runs, but when the same mold must produce tens of thousands of parts continuously, cavity wear, subtle changes in draft angle, and batch-to-batch drift in sintering shrinkage begin to surface after a certain number of shots. In the small-batch era, full inspection or hand-fitting could resolve this; in the large-batch era, that approach is no longer viable on cost or takt.

Scale also changes the supplier qualification threshold. After group procurement, leading manufacturers shifted from “multi-source procurement” to focused quality supplier consolidation; the number of active suppliers at leading manufacturers fell 30–50% compared with before group procurement, while procurement value per supplier increased 1–2 times. In other words, customers are not adding suppliers — they are narrowing the supplier pool and enlarging each supplier’s share. Whether a supplier survives this screening depends on its ability to prove, in a verifiable way, that every unit in a large batch falls within the same process window.

III. The Window for Domestic Suppliers Is Not “Cheaper” — It Is “Can Your Delivery Cadence Keep Up”

Another underestimated variable in the second half of group procurement is delivery elasticity.

Lead times for imported precision parts lengthened broadly in 2026, with the previous roughly 45-day cycle extended to 3–6 months, and expedite fees typically reaching 1.5–2 times the original price. Domestic suppliers can hold standard lead times at 2–4 weeks, with expedited orders completed in 5–7 days, and show visibly greater tolerance for order-volume fluctuations. For OEMs that need to stock regional markets quickly after winning group procurement, this delivery elasticity is itself part of supply chain competitiveness.

But fast delivery does not mean sacrificing consistency. The real threshold for domestic substitution is not “can you make it,” but whether batch records and quality documentation can support the customer’s compliance audits while delivery is being accelerated. Under group procurement, OEMs face fulfillment verification from medical insurance authorities and quality traceability requirements from the registration system. Suppliers’ MES batch records, material lot traceability, and process parameter archives are shifting from “bonus points” to must-check items during supplier audits.

IV. Yujiaxin’s Process Footing on This Supply Chain

Shenzhen Yujiaxin Technology Co., Ltd. has built capabilities in medical device precision components that map directly onto what this round of order-structure change demands.

At the category level, Yujiaxin already covers laparoscopic stapler cartridge slots, ultrasonic surgical scalpel tips, laparoscopic surgical instrument graspers, and single-use surgical jaw heads — categories tied to group procurement — using metal injection molding as the core process, supplemented by precision CNC machining and precision gear forming. These categories sit precisely in the minimally invasive surgical consumables segment where the “fewer SKUs, larger batches” pattern is most pronounced.

At the batch-capability level, Yujiaxin’s GJB9001C-2017 military certification covers full-process quality control for complex structural hardware machining. The system’s requirements for batch consistency, process records, and traceability chains align with the underlying logic customers examine during supplier audits under group procurement. The ISO 13485 quality management system experience shown on its site directly addresses medical device components’ compliance requirements for traceability and batch consistency. For customers shifting from “many varieties, small batches” to “fewer SKUs, larger batches,” this system capability answers the question “is unit 10,000 the same as unit 1” more convincingly than a single-piece precision specification.

Conclusion

Competition in the second half of group procurement is shifting from “quoting capability” to “batch consistency capability.” Order concentration on fewer SKUs means every surviving supplier must carry a larger volume across a narrower category set, and process window stability, mold life management, and batch traceability completeness will all be tested at amplified scale. Shenzhen Yujiaxin Technology Co., Ltd. has been deeply engaged in build-to-print custom machining of precision metal components for over 20 years, with full-process capabilities from process development to batch delivery in laparoscopic staplers, ultrasonic scalpels, and laparoscopic instruments. We are ready to work with medical device OEMs on the order-structure shift in the second half of group procurement, providing verifiable batch consistency and delivery elasticity for minimally invasive surgical consumables supply chains.

Learn more about custom precision metal parts manufacturing services: https://www.szyujiaxin.com/en/